Teva Pharmaceutical Industries Ltd. (TEVA) may raise its earnings forecast when it reports results next month to reflect the U.S. Food and Drug Administration’s decision on the narcolepsy drug Provigil, an analyst said. “Teva’s estimates are looking conservative following the Provigil announcement,” Natali Gotlieb, an analyst for Israel Brokerage & Investments Ltd., said in an interview in Tel Aviv. “Though Teva tends to be conservative with their guidance, there’s a chance they will increase their guidance in their first-quarter conference call.”